ATE170855T1 - Chinoline als typ iv phosphodiesterase inhibitoren - Google Patents
Chinoline als typ iv phosphodiesterase inhibitorenInfo
- Publication number
- ATE170855T1 ATE170855T1 AT94911662T AT94911662T ATE170855T1 AT E170855 T1 ATE170855 T1 AT E170855T1 AT 94911662 T AT94911662 T AT 94911662T AT 94911662 T AT94911662 T AT 94911662T AT E170855 T1 ATE170855 T1 AT E170855T1
- Authority
- AT
- Austria
- Prior art keywords
- alkyl
- quinolines
- type
- phosphodiesterase inhibitors
- arylmethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/040,731 US5455252A (en) | 1993-03-31 | 1993-03-31 | Optionally substituted 6,8-quinolines |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE170855T1 true ATE170855T1 (de) | 1998-09-15 |
Family
ID=21912628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT94911662T ATE170855T1 (de) | 1993-03-31 | 1994-03-23 | Chinoline als typ iv phosphodiesterase inhibitoren |
Country Status (14)
Country | Link |
---|---|
US (1) | US5455252A (de) |
EP (1) | EP0691966B1 (de) |
JP (1) | JP3564133B2 (de) |
KR (1) | KR100300275B1 (de) |
AT (1) | ATE170855T1 (de) |
AU (1) | AU679222B2 (de) |
DE (1) | DE69413215T2 (de) |
DK (1) | DK0691966T3 (de) |
ES (1) | ES2120028T3 (de) |
FI (1) | FI109692B (de) |
HU (2) | HUT73181A (de) |
NO (1) | NO305282B1 (de) |
NZ (1) | NZ263436A (de) |
WO (1) | WO1994022852A1 (de) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9523267D0 (en) * | 1995-11-14 | 1996-01-17 | Sandoz Ltd | Organic compounds |
JP2000510866A (ja) * | 1996-05-20 | 2000-08-22 | ダーウィン・ディスカバリー・リミテッド | Tnfとpde―ivのインヒビターとしてのキノリンスルホンアミド |
CA2252531A1 (en) * | 1996-05-20 | 1997-11-27 | Darwin Discovery Limited | Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors |
EP0934307B1 (de) | 1996-06-19 | 2011-04-27 | Aventis Pharma Limited | Substituierte azabicyclische verbindungen und ihre verwendung als inhibitoren des tnf und der cyclischen amp phosphodiestrase |
US6069151A (en) * | 1996-11-06 | 2000-05-30 | Darwin Discovery, Ltd. | Quinolines and their therapeutic use |
GB9712761D0 (en) * | 1997-06-17 | 1997-08-20 | Chiroscience Ltd | Quinolines and their therapeutic use |
IT1302677B1 (it) | 1998-10-15 | 2000-09-29 | Zambon Spa | Derivati benzazinici inibitori della fosfodiesterasi 4 |
ATE294793T1 (de) * | 1999-01-15 | 2005-05-15 | Altana Pharma Ag | Phenantrhridin-n-oxides mit pde-iv hemmender wirkung |
WO2000042017A1 (en) * | 1999-01-15 | 2000-07-20 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phenanthridine-n-oxides with pde-iv inhibiting activity |
MXPA02001830A (es) | 1999-08-21 | 2002-08-12 | Byk Gulden Lomberg Chem Fab | Combinacion sinergica de inhibidores de pde y agonista de beta 2 adrenoceptor. |
MY134008A (en) * | 1999-12-22 | 2007-11-30 | Merck Frosst Canada Inc | Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors |
US6410563B1 (en) | 1999-12-22 | 2002-06-25 | Merck Frosst Canada & Co. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
US6639077B2 (en) | 2000-03-23 | 2003-10-28 | Merck Frosst Canada & Co. | Tri-aryl-substituted-ethane PDE4 inhibitors |
MY123585A (en) | 2000-03-23 | 2006-05-31 | Merck Canada Inc | Tri-aryl-substituted-ethane pde4 inhibitors. |
AU2001261962B2 (en) | 2000-05-25 | 2005-04-21 | Merck Frosst Canada Ltd | Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor |
US6740666B2 (en) | 2000-12-20 | 2004-05-25 | Merck & Co., Inc. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
CA2447619A1 (en) | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | A composition for accelerating bone fracture healing |
MXPA03010672A (es) | 2001-05-23 | 2004-03-02 | Tanabe Seiyaku Co | Composicion para el tratamiento regenerativo de enfermedades del cartilago. |
EP1397359B1 (de) | 2001-05-24 | 2005-08-31 | Merck Frosst Canada & Co. | 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren |
DE60204463T2 (de) * | 2001-06-27 | 2006-05-18 | Merck Frosst Canada & Co, Kirkland | Substituierte 8-Arylchinoline als PDE4-Hemmer |
JO2311B1 (en) | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
ATE432261T1 (de) * | 2002-03-18 | 2009-06-15 | Merck Frosst Canada Ltd | Pde4-inhibitoren mit heterobrückensubstituiertem 8-arylchinolin |
ATE356808T1 (de) * | 2002-06-25 | 2007-04-15 | Merck Frosst Canada Ltd | 8-(biaryl)chinolin-pde4-inhibitoren |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
EA200501548A1 (ru) | 2003-04-01 | 2006-02-24 | Апплайд Резеч Системз Арс Холдинг Н.В. | Ингибиторы фосфодиэстераз при бесплодии |
CN100441185C (zh) | 2003-04-30 | 2008-12-10 | 麦克弗罗斯特加拿大有限公司 | 8-(3-联芳基)苯基喹啉磷酸二酯酶-4抑制剂 |
EP2258358A3 (de) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
WO2007025177A2 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2377530A3 (de) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation von Neurogenese durch PDE-Hemmung |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2377531A2 (de) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
ES2394971T3 (es) * | 2006-08-03 | 2013-02-07 | Rottapharm S.P.A. | Derivados de quinolinas y 6-1H-imidazo-quinazolina, agentes antiinflamatorios y analgésicos potentes nuevos |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
DK2170930T3 (da) | 2007-06-04 | 2012-11-05 | Synergy Pharmaceuticals Inc | Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
CA2728376C (en) | 2008-06-20 | 2015-05-12 | Rottapharm S.P.A. | 6-1h-imidazo-quinazoline and quinolines derivatives/mao inhibitors for treating depression |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
UY33372A (es) | 2010-05-10 | 2011-12-30 | Gilead Sciences Inc | ?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?. |
US8367829B2 (en) | 2010-05-10 | 2013-02-05 | Gilead Sciences, Inc. | Bi-functional pyrazolopyridine compounds |
WO2012018059A1 (ja) * | 2010-08-04 | 2012-02-09 | 武田薬品工業株式会社 | 複素環化合物 |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
ES2664873T3 (es) | 2011-03-01 | 2018-04-23 | Synergy Pharmaceuticals Inc. | Proceso de preparación de agonistas de guanilato ciclasa C |
EP2804603A1 (de) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Betazellen-replikation für promoterverbindungen und verwendungsverfahren dafür |
EP2958577A2 (de) | 2013-02-25 | 2015-12-30 | Synergy Pharmaceuticals Inc. | Guanylat-cyclase-rezeptoragonisten zur verwendung bei der darmreinigung |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
KR102272746B1 (ko) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법 |
KR20220147691A (ko) | 2013-08-09 | 2022-11-03 | 알데릭스, 인코포레이티드 | 인산염 수송을 억제하기 위한 화합물 및 방법 |
US10398689B2 (en) | 2015-12-22 | 2019-09-03 | Jiangsu Hengrui Medicine Co., Ltd. | Benzopiperidine derivative, preparation method thereof and medical use thereof |
JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス, インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4563460A (en) * | 1984-01-13 | 1986-01-07 | William H. Rorer, Inc. | Quinoline and quinazoline derivatives for treating gastrointestinal motility dysfunctions |
US4672029A (en) * | 1984-12-06 | 1987-06-09 | Eastman Kodak Company | Color-forming couplers and their use in the analytical determination of hydrogen peroxide or other analytes |
CA1336714C (en) * | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
DE3935491A1 (de) * | 1989-10-25 | 1991-05-02 | Bayer Ag | Substituierte (chinolin-2-yl-methoxy)phenyl-carbonylharnstoffe |
-
1993
- 1993-03-31 US US08/040,731 patent/US5455252A/en not_active Expired - Lifetime
-
1994
- 1994-03-23 AT AT94911662T patent/ATE170855T1/de not_active IP Right Cessation
- 1994-03-23 ES ES94911662T patent/ES2120028T3/es not_active Expired - Lifetime
- 1994-03-23 AU AU64129/94A patent/AU679222B2/en not_active Ceased
- 1994-03-23 HU HU9502845A patent/HUT73181A/hu not_active Application Discontinuation
- 1994-03-23 DE DE69413215T patent/DE69413215T2/de not_active Expired - Fee Related
- 1994-03-23 JP JP52213694A patent/JP3564133B2/ja not_active Expired - Fee Related
- 1994-03-23 EP EP94911662A patent/EP0691966B1/de not_active Expired - Lifetime
- 1994-03-23 KR KR1019950704211A patent/KR100300275B1/ko not_active IP Right Cessation
- 1994-03-23 NZ NZ263436A patent/NZ263436A/xx unknown
- 1994-03-23 WO PCT/US1994/003004 patent/WO1994022852A1/en active IP Right Grant
- 1994-03-23 DK DK94911662T patent/DK0691966T3/da active
-
1995
- 1995-04-24 HU HU95P/P00111P patent/HU210816A9/hu unknown
- 1995-09-29 FI FI954651A patent/FI109692B/fi not_active IP Right Cessation
- 1995-09-29 NO NO953879A patent/NO305282B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HUT73181A (en) | 1996-06-28 |
JPH08511238A (ja) | 1996-11-26 |
WO1994022852A1 (en) | 1994-10-13 |
JP3564133B2 (ja) | 2004-09-08 |
DK0691966T3 (da) | 1999-02-08 |
NO953879L (no) | 1995-11-22 |
AU679222B2 (en) | 1997-06-26 |
FI109692B (fi) | 2002-09-30 |
DE69413215T2 (de) | 1999-01-28 |
AU6412994A (en) | 1994-10-24 |
EP0691966A1 (de) | 1996-01-17 |
US5455252A (en) | 1995-10-03 |
ES2120028T3 (es) | 1998-10-16 |
EP0691966B1 (de) | 1998-09-09 |
FI954651A0 (fi) | 1995-09-29 |
NZ263436A (en) | 1997-08-22 |
NO305282B1 (no) | 1999-05-03 |
KR100300275B1 (ko) | 2001-10-22 |
HU210816A9 (en) | 1995-08-28 |
DE69413215D1 (en) | 1998-10-15 |
NO953879D0 (no) | 1995-09-29 |
HU9502845D0 (en) | 1995-11-28 |
FI954651A (fi) | 1995-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE170855T1 (de) | Chinoline als typ iv phosphodiesterase inhibitoren | |
NO20003232L (no) | Inhibering av raf-kinase ved anvendelse av substituerte heterosykliske ureaforbindelser | |
AP1246A (en) | Substituted pyrazoles as p38 Kinase inhibitors. | |
ATE198334T1 (de) | 1,2,4-triazolo(1,5-c)pyrimidin-heterocyclische analoge mit antagonistischer aktivität auf dem adenosine a2a rezeptor | |
NO20003231D0 (no) | Inhibering av RAF-kinase ved anvendelse av aryl- og heteroarylsubstituerte heterosykliske ureaforbindelser | |
CA2339630A1 (en) | Carboline derivatives as cgmp phosphodiesterase inhibitors | |
YU35601A (sh) | SUPSTITUISANI PIRAZOLI KAO INHIBITORI p38 KINAZE | |
EP1006114A4 (de) | Pyrazolderivate und sie enthaltende cox-inhibitoren | |
ES2109239T3 (es) | 5-(1-aminociclohexil)-2(1h)-piridinona y compuestos relacionados. | |
PE46699A1 (es) | Compuesto derivado de indol | |
ATE224391T1 (de) | Substituierte imidazo(1,2a)azine als selective inhibitoren der cox-2 | |
NO984033L (no) | Nye indol og indazol forbindelser, en fremgangsmÕte ved deres fremstilling og farmas°ytiske forbindelser som inneholder dem | |
CA2307581A1 (en) | Heterocyclic compounds having nos inhibiting action | |
ES2120463T3 (es) | (piridinilamino)-benzisoxazoles y -benzoisotiazoles sustituidos un procedimiento para su preparacion y su uso como medicamentos. | |
DE69725337D1 (de) | 5-cyclo-indolverbindungen als 5-ht1d rezeptor liganden | |
ATE247121T1 (de) | Imidazolderivate als phosphodiesterase vii-hemmer | |
Osante et al. | Stereodivergent Synthesis of Hetero‐Fused Isoquinolines by Acyliminium and Metallation Methods | |
NZ316516A (en) | quinoline substituted carbamoyl carboxylic acid amides and medicaments | |
ATE318600T1 (de) | Diaryl piperidyl-pyrrol-derivate als antiprotozoenmittel | |
TW338039B (en) | Salts of inidazoline derivatives | |
MX9707187A (es) | Derivados de imidazopiridina. | |
NO994997D0 (no) | Alkaloidhalidsalter av swainsonin og fremgangsmåter ved anvendelse | |
SE0004266L (sv) | Portabel kommunikationsapparat | |
MX9704263A (es) | Derivados de imidazol como inhibidores de la proteina cinasa, en particular la tirosina cinasa del egf-r. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |